Skip to main navigation

Back to SpringWorksTx.com
Investors & Media
Contact Us
Linkedin
Twitter

Overview
News & Events
- Press Releases
- Events & Presentations
Corporate Governance
Financial Information
- SEC Filings
- Annual Reports
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Investor Resources
Investors + Media
Medical Professionals
Contact Us
Linkedin
Twitter

Press Releases

Items Per Page

Year

07 Nov 2018

SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors

PDF Version

05 Nov 2018

SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1

PDF Version

06 Sep 2018

BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors

PDF Version

05 Sep 2018

SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive Officer

PDF Version

05 Mar 2018

SpringWorks Therapeutics to Present at Cowen and Company’s 38th Annual Health Care Conference

PDF Version

05 Jan 2018

SpringWorks Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

PDF Version

25 Sep 2017

SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs

PDF Version

Pagination

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Current page 11

Displaying 101 - 107 of 107

Springworks - Toolkits

Print Page
Email Alerts
RSS Feeds
Investor Contacts

Request E-mail Alerts

Social Links

Footer 1

Who We Are
Focus Areas

Footer 2

Pipeline
Careers
- View Opportunities
- Desmoid Tumor Commercial Team

Footer 3

Patients
Contact

Footer 4

Investors & Media

© 2023 SpringWorks Therapeutics. All rights reserved.

Copyright Links

Privacy Policy
Terms of Use
Cookie Policy